Melanotan II

Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona. Its cyclic structure — formed by a lactam bridge between aspartic acid and lysine — confers metabolic stability and, critically, non-selective binding to all five melanocortin receptors (MC1R through MC5R). This broad receptor activation profile is both the source of its diverse effects and the root of its safety concerns.

The tanning mechanism is driven by MC1R activation on dermal melanocytes: MC1R → Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → MITF transcription factor activation → upregulation of tyrosinase, TRP-1, and TRP-2 → eumelanin synthesis and deposition. This produces genuine melanin-based pigmentation from within the skin — fundamentally different from topical self-tanners that stain the stratum corneum with dihydroxyacetone. The tanning occurs independent of UV exposure, which is the basis of the original "sunless tanning" concept, though UV exposure dramatically amplifies melanogenesis and raises safety concerns about melanocyte stimulation in UV-damaged skin.

MC4R activation in the hypothalamus drives the additional effects: sexual arousal through oxytocinergic-parasympathetic pathways and appetite suppression through inhibition of orexigenic NPY/AgRP neurons in the arcuate nucleus. MC3R contributes to energy homeostasis and natriuresis regulation. MC5R activation affects exocrine gland secretion. This multi-receptor, multi-effect profile — tanning + libido + appetite suppression — has made Melanotan II one of the most widely used cosmetic peptides globally despite its unapproved status and active discouragement by health authorities in most countries.

Melanotan II was developed in the 1990s at the University of Arizona by a research team investigating α-MSH analogues as potential sunless tanning agents — a concept with public-health appeal as a skin-cancer prevention strategy by providing melanin-based UV protection without sun exposure. During early clinical studies, male subjects unexpectedly reported spontaneous erections, leading to the discovery of melanocortin-mediated sexual-arousal pathways and ultimately to the development of PT-141 (bremelanotide) as a selective sexual-desire therapeutic.

Unlike PT-141, Melanotan II was never advanced to FDA approval. Its non-selective melanocortin profile, cosmetic (rather than medical) use case, and safety concerns — particularly unpredictable darkening of moles and freckles that could mask melanoma warning signs — have prevented any regulatory authorization. Australia's TGA has actively banned the compound. Despite this, Melanotan II has achieved widespread global use through online vendors and word-of-mouth networks, making it one of the most extensively used unregulated peptides worldwide. The FDA-approved analogue Melanotan I (afamelanotide, Scenesse) is a linear, MC1R-selective peptide approved only for erythropoietic protoporphyria — not for cosmetic tanning.

Store lyophilized Melanotan II at -20°C in a light-protected, desiccated container. The cyclic lactam structure provides good stability; the lyophilized powder is stable >24 months under recommended conditions. Avoid moisture ingress — the peptide is hygroscopic and the cyclic structure can be hydrolyzed under prolonged humid conditions.

After reconstitution with bacteriostatic water, Melanotan II should be stored at 2–8°C and used within 21 days. The solution should be clear and colorless; any discoloration or turbidity indicates degradation. Due to the loading-then-maintenance research protocol, a single 10mg vial typically covers a full loading phase (20–40 days at 0.25–0.5 mg/day) with the maintenance phase requiring additional vials. Some researchers aliquot the reconstituted solution into sterile single-use vials and freeze at -20°C for extended storage (up to 90 days), though only a single freeze-thaw cycle is recommended. Nausea is common (>50% of subjects) during initial loading — this is MC4R-mediated and typically diminishes after the first 3–5 administrations.